---
document_datetime: 2025-12-18 09:19:16
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/breyanzi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: breyanzi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.8024573
conversion_datetime: 2026-01-03 12:26:08.212991
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Breyanzi

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                    | Scope                                                                                                                             | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB / EMA/VR/0000310085 | B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.z Other variation - | 26/11/2025                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                       | Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                    |                                                                                                                                                                                                                                                                                           |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000292821 | B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 10/11/2025 | N/A        |                    |                                                                                                                                                                                                                                                                                           |
| Variation type II / EMA/VR/0000264124 | This was an application for a group of variations. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted A grouped application consisting of: C.I.4: Update of section 5.1 of the SmPC in order to update efficacy information based on final results from study JCAR017-BCM-003; this is a global randomized multicenter phase 3 | 16/10/2025 | 21/11/2025 | SmPC and Labelling | The group of variations concern update of efficacy data based on the study JCAR017-BCM-003 and safety data in pooled data for studies TRANSFORM BCM-003, PILOT 17006 and TRANSCEND WORLD, cohort 2 BCM-001. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

|                                       | JCAR017 to standard of care in adult subjects with high-risk, transplant-eligible relapsed or refractory aggressive B-cell Non- Hodgkin lymphomas (TRANSFORM). In addition, final study reports for studies 017006 and JCAR017-BCM-001 Cohort 2 are submitted to support the main scope. C.I.4: Update of section 4.8 of the SmPC in order to update information for the safety and immunogenicity based on pooled final data form the three follow up studies: (TRANSFORM BCM-003, PILOT 17006 and TRANSCEND WORLD, cohort 2 BCM-001). In addition, the MAH took the opportunity to remove the dose verification worksheet statement from the Labelling.   |            |            |                        |                                                                               |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000265024 | This was an application for a group of variations. B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.e Change outside the approved specifications limits range - Accepted C.I.6 Change(s) to therapeutic indication(s) - C.I.6.a Addition of a new therapeutic indication or modification of an approved one - Accepted                                                                                                                                                                                                                                                                                      | 16/10/2025 | 21/11/2025 | SmPC, Labelling and PL | Please refer to Scientific Discussion 'Breyanzi-H-C- 4731- EMA/VR/0000265024' |

<div style=\"page-break-after: always\"></div>

| Variation type II / EMA/VR/0000272242   | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.2, 4.4, 4.7 and 4.8 of the SmPC in order to update the post- treatment safety monitoring information based on clinical trials and real-world data. The Package leaflet section and the annex II are updated in accordance. The applicant also took the occasion to update the list of local representatives for Iceland in the package leaflet. Version 9.1 of the RMP has also been submitted.   | 16/10/2025   | 21/11/2025   | SmPC, Annex II and PL   | SmPC new text: Patients should be monitored 2 3 times during the first week following infusion, at the qualified treatment centre for signs and symptoms of CRS/neurologic toxicities. Frequency of monitoring after the first week should be carried out at the physician's discretion, and should be continued for at least 2 weeks after infusion. Patients and caregivers should be informed about the potential late onset of neurologic toxicities and instructed to seek immediate medical attention if patients experience any signs or symptoms of neurologic toxicities. Due to the potential for neurologic events, including altered mental status or seizures with Breyanzi, patients receiving Breyanzi should refrain from driving or operating heavy or potentially dangerous machines for at least 4 weeks after Breyanzi infusion, or longer at the physician's discretion For more information, please refer to the Summary of Product Characteristics.   |
|-----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000293528   | B.II.d.2 Change in test procedure for the finished product - B.II.d.2.d Other changes to a test procedure (including replacement or addition) - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 16/09/2025   | N/A          |                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Variation type IB / EMA/VR/0000288460   | This was an application for a group of variations. B.I.b.1 Change in the specification parameters and/or limits of an active                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 02/09/2025   | N/A          |                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|                                       | substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z Other changes - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.e Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate - Accepted B.III.1.b European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/ intermediate/or excipient - B.III.1.b.3 Updated certificate from an already approved manufacturer - Accepted   |            |     |                                                                                                                                                                                                                                                       |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000290623 | B.I.b) Control of active substance - B.I.b.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 29/08/2025 | N/A |                                                                                                                                                                                                                                                       |
| Variation type IB / EMA/VR/0000288030 | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 12/08/2025 | N/A | To update the RMP to add follicular lymphoma patients infused with liso-cel in the post marketing setting in the study population of study JCAR017 BCM-005, based on the updated post-authorization safety study (PASS) protocol that was endorsed by |

<div style=\"page-break-after: always\"></div>

|                                       | C.I.11.z (Type IB) - To update the RMP to add follicular lymphoma patients infused with liso-cel in the post marketing setting in the study population of study JCAR017 BCM- 005, based on the updated post- authorization safety study (PASS) protocol that was endorsed by PRAC. In addition, the MAH took the opportunity to implement an editorial change to correct the milestone dates for the Transgene assay service listed in Table 3.3-1, aligning them with the European Commission's decision date.   |            |     | PRAC.   |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------|
| Variation type IB / EMA/VR/0000273146 | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.f Changes to quality control testing arrangements for the active substance-replacement or addition of a site where batch control/testing takes place - Accepted   | 04/08/2025 | N/A |         |
| Variation type IB / EMA/VR/0000269488 | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 25/07/2025 | N/A |         |

<div style=\"page-break-after: always\"></div>

|                                          | period or storage conditions of the active substance where no Ph. Eur. Certificate of Suitability covering the retest period is part of the approved dossier - B.I.d.1.c Change to an approved stability protocol - Accepted B.I.d.1.a Re-test period/storage period - B.I.d.1.a.4 Extension or introduction of a re- test period/storage period supported by real time data - Accepted   |            |     |
|------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type II / EMA/VR/0000249056    | B.I.e) Design Space and post-approval change management protocols - B.I.e.2 Introduction of a post approval change management protocol related to the active substance - Accepted                                                                                                                                                                                                         | 24/07/2025 | N/A |
| PASS / EMA/PASS/0000269320               | - -                                                                                                                                                                                                                                                                                                                                                                                       | 10/07/2025 | N/A |
| Variation type IA_IN / EMA/VR/0000272241 | B.V.a.1 Inclusion of a new, updated or amended Plasma Master File in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - B.V.a.1.d Inclusion of an updated/amended Plasma Master File when changes do not affect the properties of the finished product - Accepted                                                                                     | 20/05/2025 | N/A |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000257499    | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted C.I.11.z - to provide a consolidated Risk Management Plan (RMP) following a positive CHMP opinion for procedures EMEA/H/C/004731/II/0043/G and EMEA/H/C/004731/IB/0051.   | 10/04/2025   | N/A   |             |
|------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------|
| Variation type IA_IN / EMA/VR/0000246077 | B.V.a.1 Inclusion of a new, updated or amended Plasma Master File in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - B.V.a.1.d Inclusion of an updated/amended Plasma Master File when changes do not affect the properties of the finished product - Accepted                                                                                              | 06/02/2025   | N/A   |             |
| PSUR / EMA/PSUR/0000269003               | - -                                                                                                                                                                                                                                                                                                                                                                                                |              |       | Maintenance |